PYXS (Pyxis Oncology) Institutional Ownership: 44.71% (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PYXS Pyxis Oncology Inc PYXS
26 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Pyxis Oncology Institutional Ownership?

Pyxis Oncology PYXS +13.17% 26 Institutional Ownership is 44.71% as of Aug. 13, 2026. GuruFocus rates PYXS with a GF Score™ of 26/100. The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Pyxis Oncology's institutional ownership is 44.71%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Pyxis Oncology's Insider Ownership is 9.79%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Pyxis Oncology's Float Percentage Of Total Shares Outstanding is 73.90%.

Pyxis Oncology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Pyxis Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pyxis Oncology Institutional Ownership Chart

Pyxis Oncology Historical Data

The historical data trend for Pyxis Oncology can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 6.18 8.21 7.30 8.08 8.09 7.50 7.47 7.45 7.36 7.38
PYXS
26GF Score
Pyxis Oncology Inc PYXS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pyxis Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 44.71% mean?
Pyxis Oncology (PYXS) has a Institutional Ownership of 44.71% as of Aug. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pyxis Oncology and its competitors.
Is Pyxis Oncology's Institutional Ownership too high?
Pyxis Oncology's current Institutional Ownership is 44.71%. Overall, Pyxis Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's Institutional Ownership compare to ORMP and CAMP?
Pyxis Oncology's Institutional Ownership of 44.71% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Pyxis Oncology and its competitors. Pyxis Oncology's current Institutional Ownership is 44.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current Institutional Ownership of 44.71%. The current Institutional Ownership is 44.71%. Pyxis Oncology's overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current Institutional Ownership is 44.71% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pyxis Oncology Business Description

Address 321 Harrison Avenue, Boston, MA, USA, 02118
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
26GF Score

Get the complete analysis for PYXS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price